Additionally, guidelines recommend GLP-1-RAs with proven cardiovascular (CV) benefit as one of the preferred options for add-on therapy in patients with T2DM and established atherosclotic CV disease after metformin and lifestyle intervention (7). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.